ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Virios Therapeutics Inc

Virios Therapeutics Inc (VIRI)

0.4791
-0.0046
(-0.95%)
Closed March 29 04:00PM
0.4997
0.0206
(4.30%)
After Hours: 07:46PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.4997
Bid
0.4709
Ask
0.4998
Volume
427,759
0.42 Day's Range 0.53
0.279 52 Week Range 2.42
Market Cap
Previous Close
0.4837
Open
0.49
Last Trade Time
Financial Volume
$ 206,216
VWAP
0.482084
Average Volume (3m)
388,126
Shares Outstanding
19,257,937
Dividend Yield
-
PE Ratio
-1.71
Earnings Per Share (EPS)
-0.28
Revenue
-
Net Profit
-5.3M

About Virios Therapeutics Inc

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people wh... Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Virios Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VIRI. The last closing price for Virios Therapeutics was $0.48. Over the last year, Virios Therapeutics shares have traded in a share price range of $ 0.279 to $ 2.42.

Virios Therapeutics currently has 19,257,937 shares outstanding. The market capitalization of Virios Therapeutics is $9.05 million. Virios Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

VIRI Latest News

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

00018188442023FYfalseVirios Therapeutics, Inc.18330390000.0001P10YP6M000018188442023-03-182023-03-1800018188442021-12-212021-12-210001818844srt:MinimumMember2023-01-012023-12-310001818844srt:Maximu...

Form 8-K - Current report

0001818844false00018188442024-03-012024-03-01​​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549​FORM 8-K​CURRENT REPORTPURSUANT TO...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

00018188442023FYfalseVirios Therapeutics, Inc.18330390000.0001P10YP6M000018188442023-03-182023-03-1800018188442021-12-212021-12-210001818844srt:MinimumMember2023-01-012023-12-310001818844srt:Maximu...

Form 8-K - Current report

0001818844false00018188442024-02-292024-02-29​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549​FORM 8-K​CURRENT REPORTPURSUANT TO SECTION 13...

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.137337.88631346580.36240.62880.33117345120.45258254CS
40.110728.45758354760.3890.62880.2795821480.42376101CS
12-0.0529-9.572927976840.55260.940.2793881260.45793018CS
26-0.4303-46.26881720430.931.040.2793932970.61382893CS
520.089721.87804878050.412.420.27910708370.98070514CS
156-4.8303-90.62476547845.339.11090.2189514882701.11098197CS
260-13.2603-96.368459302313.7614.390.2189514790001.59870879CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

VIRI Discussion

View Posts
Carjockey2 Carjockey2 19 hours ago
Holding up very nicely here

$VIRI
👍️ 1
koolmc koolmc 2 days ago
viri .50's again
👍️ 1
Carjockey2 Carjockey2 2 days ago
Those are long gone..just like last year when we ran from current levels to $2.45

👍️0
longrichard longrichard 2 days ago
Why? Wait for .30's
👍️0
limer814 limer814 2 days ago
Added more .46s
👍️0
skydog526 skydog526 3 days ago
Greg is a horrible CEO. Think about why. Releasing little nothing bits of snooze, and they are still behind on enrollment. He's responsible for the languishing stock price and I bet he would pull the rug out on retail as before.
👍️0
Carjockey2 Carjockey2 3 days ago
Great PR but I'm looking for something a little more meaty..I think we get it very soon..
Cheers
👍️0
limer814 limer814 3 days ago
News people!!
https://www.globenewswire.com/news-release/2024/03/26/2852441/0/en/Virios-Therapeutics-Announces-Publication-of-International-Patent-for-IMC-2-Covering-Antiviral-Treatment-of-Long-COVID.html
👍️0
jb55 jb55 3 days ago
ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced that the World Intellectual Property Organization (WIPO) has published Virios' global patent application titled "Valacyclovir and Celecoxib for the Treatment of Alzheimer's and COVID-19", which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.

An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety. Combination treatment with valacyclovir and celecoxib is presently being assessed in a double blind, placebo-controlled study under the direction of Dr. Lucinda Bateman, MD, supported by an unrestricted, investigational grant provided by the Company to the Bateman Horne Center. Results from this important trial are expected this summer.

The 2024 National Center for Health Statistics Household Pulse Survey estimates that 17.6% of the US population have experienced LC, representing upwards of 45 million potential adult patients, since the pandemic started in November of 2019. Previous estimates suggest that up to 10 million children in the US have also experienced LC. There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.

A multitude of studies suggest that while LC is a consequence of SARS-CoV-2 virus infection, the development of LC seems related to immune system dysfunction and complement activation. It has been postulated that an exhausted immune response to COVID-19 enables reactivation of previously dormant herpesviruses. Reactivated herpesviruses such as Epstein-Barr virus (EBV) may be associated with fatigue and cognitive dysfunction. Fatigue and cognitive dysfunction are predominant LC symptoms.
👍️0
skydog526 skydog526 3 days ago
$VIRI GO RAHRAHRAH
👍️0
skydog526 skydog526 3 days ago
LOL
👍️0
zooey zooey 3 days ago
LOI?
👍️0
longrichard longrichard 4 days ago
LOl
👍️0
DavidLeeRoth DavidLeeRoth 4 days ago
This acquisition would be a drop in the bucket for Pfizer😎 Show me the MONEY!!!!
👍️0
DavidLeeRoth DavidLeeRoth 4 days ago
Taken from another board, but this should make you feel great about the possibility of VIRI being bought out😎 If they take these drugs to market on their own, then that’s awesome too!!
👍️0
limer814 limer814 4 days ago
And again
👍️0
koolmc koolmc 4 days ago
viri .50's again
👍️0
koolmc koolmc 4 days ago
lol
👍️0
limer814 limer814 4 days ago
You can sprinkle your dust on me any time !!!
👍️0
lumpina lumpina 4 days ago
may the fairies be with us, and their magic dust
👍️0
Carjockey2 Carjockey2 4 days ago
Sprinkled some green fairy dust..

Lfg

$VIRI

All I know is I got back in slightly lower than I got in before the run last year..

Wink
👍️ 1 😎 1
skydog526 skydog526 4 days ago
He was unloading this POS after he had loaded it. That's how it works.
👍️0
glenn1919 glenn1919 6 days ago
VIRI...........................https://stockcharts.com/h-sc/ui?s=VIRI&p=W&b=5&g=0&id=p86431144783
👍️0
lumpina lumpina 7 days ago
come on cj. sprinkle some of your lucky dust and get this moving again
👍️0
koolmc koolmc 7 days ago
would be sweet if it 80's again
👍️0
koolmc koolmc 7 days ago
yep nice tweet frank playing it again
👍️0
JACKPOT JACKPOT 7 days ago
I bought back in myself
👍️ 1
PStockPickz PStockPickz 7 days ago
Grabbed a chunk here we go!
👍️0
limer814 limer814 7 days ago
Got me some .46s lol , back in the wagon again
👍️0
DavidLeeRoth DavidLeeRoth 7 days ago
Sweeeeeeeet😎 Looks like we’re heading back to dollar land!! VIRI LONG💰
👍️0
Carjockey2 Carjockey2 7 days ago
Looks that way..

Joined ya ..back in $VIRI.. 😀 https://t.co/bhO1hLtsWg— Carjockey2 (@cocomoco1234567) March 22, 2024

I haven't looked at $VIRI for a while..wow.. I bought higher than where we are now last year before the tremendous run!!!!!! https://t.co/KrEDetDzsC— Carjockey2 (@cocomoco1234567) March 22, 2024
👍️0
zooey zooey 1 week ago
Nice tweet!

Exciting news! Our phase 2 clinical trial for Long COVID, featuring valacyclovir and celecoxib, is currently in progress, and we're thrilled to announce that we've already enrolled 50% of our target participants!

Learn more & get involved.
➡️ Click here: https://t.co/L1rcD74VJj pic.twitter.com/vAHs5yqZoc— Bateman Horne Center (@BatemanHorne) March 21, 2024
👍️0
DavidLeeRoth DavidLeeRoth 1 week ago
VIRI getting active on X😎💰

Great work @BatemanHorne pic.twitter.com/rcB1l9mjyH— Virios Therapeutics (@ViriosBiotech) March 21, 2024
👍️0
DavidLeeRoth DavidLeeRoth 1 week ago
Bateman Horne Update!! VIRI👍👍

Exciting news! Our phase 2 clinical trial for Long COVID, featuring valacyclovir and celecoxib, is currently in progress, and we're thrilled to announce that we've already enrolled 50% of our target participants!

Learn more & get involved.
➡️ Click here: https://t.co/L1rcD74VJj pic.twitter.com/vAHs5yqZoc— Bateman Horne Center (@BatemanHorne) March 21, 2024
👍️0
zooey zooey 1 week ago
Absolutley another run is coming. Just need patience..
👍️0
valleybenedetto valleybenedetto 1 week ago
I added a bunch last 2 days. I'm thinking another run is coming.
👍️ 1
0210 0210 1 week ago
lololol viri....again?😂🤣
👍️0
skydog526 skydog526 2 weeks ago
https://www.openevidence.com/ask/2e6b9511-1ef1-42c2-92cc-d4e3e7cb4813

Becoming mainstream now.
👍️0
pinkslipjunkie pinkslipjunkie 3 weeks ago
Pardon me...but you need to go pump your dog.
👍️0
skydog526 skydog526 3 weeks ago
Clown man I know you on Iflub over a decade now we know the drill clown man.
💩 1
skydog526 skydog526 3 weeks ago
Clown man they haven't set an RS ratio because it doesn't need to be implemented yet clown short clown man they have months to decide if so clown man.
👍️0
skydog526 skydog526 3 weeks ago
No she's a carclown this POS was pumped via a paid promo I don't know if that she it he works for them based on it's trading it she is not.
👍️0
pinkslipjunkie pinkslipjunkie 3 weeks ago
It only seems to get worse after that...90% of the time anyway...
👍️0
Money-train Money-train 3 weeks ago
There’s no way I’m holding into a R/S!
👍️0
pinkslipjunkie pinkslipjunkie 3 weeks ago
LOL...right.
👍️0
lumpina lumpina 3 weeks ago
well that narrows it down a bit. lol
👍️0
pinkslipjunkie pinkslipjunkie 3 weeks ago
Never mind I found the ratio on the Feb 2nd proxy

(1) an amendment to our Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-25, with the exact ratio and effective time of the reverse stock split to be determined by our Board of Directors; and
👍️0
pinkslipjunkie pinkslipjunkie 3 weeks ago
Surprised they have not set a ratio yet....or do they not need to ever announce the ratio until it does split...I thought there had to be a ratio announced prior.
Not yet. This 8-K just shows they voted to approve a split on March 1st.
👍️0
lumpina lumpina 3 weeks ago
we need carjockey
👍️0
skydog526 skydog526 3 weeks ago
We need pump this POS!
👍️0

Your Recent History

Delayed Upgrade Clock